MedPath

Multicenter prospective observational study on minimal residual disease of ALL after allogeneic transplantation using circulating cell-free tumor DNA KSGCT1901(ctALL)

Not Applicable
Recruiting
Conditions
Acute lymphocytic leukemia
Registration Number
JPRN-UMIN000039899
Lead Sponsor
Kanto Study Group for Cell Therapy
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
55
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are otherwise classified as unfit by the attending physicians for this research.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
One-year cumulative incidence of ALL relapse
Secondary Outcome Measures
NameTimeMethod
One-year overall survival, Somatic gene mutation, gene expression and immune cell profile at initial diagnosis and relapse
© Copyright 2025. All Rights Reserved by MedPath